Paper Details

  1. Home
  2. Paper Details

Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy.

Author: AlbertsD S, BertoliL, CramerM B, EisenbergP, HahneW F, KhojastehA, ModianoM R, PleziaP, YeildingA

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Dolasetron mesylate 1.8 mg/kg was more effective than 0.6 mg/kg in preventing nausea and vomiting in patients receiving high-dose cisplatin chemotherapy for the first time. Complete responses were achieved in 55% of patients receiving 1.8 mg/kg compared to 31% receiving 0.6 mg/kg. The most common side effects were mild headache and diarrhea.
Paper Details　
Original Abstract of the Article :
This randomized, double-blind, parallel-group, multicenter study compared the antiemetic effectiveness, safety, and tolerability of two different intravenous (i.v.) doses of dolasetron mesylate (0.6 and 1.8 mg/kg) in cancer patients receiving their first course of high-dose cisplatin-containing chem...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/00000421-199612000-00018

データ提供：米国国立医学図書館（NLM）

Fighting Nausea in the Desert of Chemotherapy: Exploring the Antiemetic Effects of Dolasetron

Chemotherapy, like a scorching desert journey, can be accompanied by unpleasant side effects. This study explores the antiemetic effects of dolasetron, a medication used to prevent and treat nausea and vomiting associated with chemotherapy. The authors conducted a randomized, double-blind trial to compare the effectiveness of two different doses of dolasetron in patients receiving high-dose cisplatin chemotherapy.

The study found that a higher dose of dolasetron (1.8 mg/kg) was significantly more effective in preventing and controlling nausea and vomiting than a lower dose (0.6 mg/kg). The authors observed a higher rate of complete response and a longer time to the first emetic episode in patients who received the higher dose. The study also reported that dolasetron was generally well-tolerated, with mild to moderate side effects.

A Beacon of Hope in the Desert of Nausea

The findings of this study offer a beacon of hope in the desert of chemotherapy-induced nausea and vomiting. The higher dose of dolasetron demonstrated greater effectiveness in providing relief, offering patients a better chance of navigating this difficult journey.

Navigating the Desert of Chemotherapy

This study highlights the importance of collaborating with healthcare providers to manage chemotherapy-related side effects. Patients can discuss potential treatment options, including antiemetic medications, to help minimize discomfort and improve their overall quality of life.

Dr.Camel's Conclusion

This study provides valuable insights into the antiemetic effectiveness of dolasetron. The findings suggest that a higher dose of dolasetron can provide more effective relief from chemotherapy-induced nausea and vomiting. It emphasizes the importance of individualized treatment approaches to help patients navigate the desert of chemotherapy side effects.

Date :
  1. Date Completed 1996-12-26
  2. Date Revised 2019-09-05
Further Info :

Pubmed ID

8931684

DOI: Digital Object Identifier

10.1097/00000421-199612000-00018

Related Literature

Article Analysis
・Effects of dolasetron injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.